Arthritis medicines and cardiovascular events- "House of coxibs"

Article Abstract:

Physicians, patients and the general public are dealing with confusional state regarding the cardiovascular safety of medicines for arthritis. The National Cancer Institute announced the premature cessation of a trial of celecoxib known as Adenoma Prevention with Celecoxib (APC) due to significant excess of cardiovascular death, myocardial infarction (MI) and stroke on 17 December 2004.

Author: Topol, Eric J.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
Research and Development in the Physical, Engineering, and Life Sciences, Science & research, Research and Testing Services, Arthritis R&D, Research, Cardiovascular diseases, Risk factors, Arthritis research, Celecoxib

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Protein carbamylation links inflammation, smoking, uremia and atherogenesis

Article Abstract:

Studies about the cyanate formation and protein carbamylation, which is believed to promote vascular dysfunction during end-stage renal disease, are presented. The protein carbamylation mechanism is found directly linked to inflammation, smoking, uremia and coronary artery disease pathogenesis.

Author: Topol, Eric J., Hazen, Stanley L., Rodriguez, E. Rene, Horkko, Sohvi, Nicholls, Stephen J., Barnard, John, Zeneng Wang, Kummu, Outi, Reynolds, Wanda F., DiDonato, Joseph A.
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2007
Health aspects, Coronary heart disease, Smoking, Protein research

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Care and treatment
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.